Valion Bio
VBIO
7 hedge funds and large institutions have $112K invested in Valion Bio in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
254% more capital invested
Capital invested by funds: $31.7K → $112K (+$80.3K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0.18% more ownership
Funds ownership: 0.07% → 0.25% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.96K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$173 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$28.9K |
| 2 |
Citigroup
New York
|
-$1.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $86.4K | +$81.1K | +2,822 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $20.6K | +$19.1K | +663 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $4.24K | +$2.96K | +103 | +286% |
|
|
4
UBS Group
Zurich,
Switzerland
| $391 | +$173 | +6 | +86% |
|
5
Osaic Holdings
Scottsdale,
Arizona
| $262 | – | – | – |
|
|
6
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $90 | +$86 | +3 | New |
|
7
Wells Fargo
San Francisco,
California
| $20 | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$28.9K | -982 | Closed |
|
|
9
Citigroup
New York
| – | -$1.22K | -41 | Closed |
|
VBIO Hedge Fund Activity: Q4 2023 in Review
7 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2023, worth a combined $112K — up 254% from $31.7K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VBIO positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $81.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $28.9K sold.
- 7 institutional investors held Valion Bio (VBIO) as of Q4 2023, up from 6 in Q3 2023.
- Funds reported $112K of Valion Bio stock for Q4 2023, up 254% quarter-over-quarter.
- 3 funds opened new Valion Bio positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Valion Bio buyer in Q4 2023 was Vanguard Group, an estimated $81.1K added.
- The largest Valion Bio seller in Q4 2023 was Citadel Advisors, an estimated $28.9K sold.
Based on aggregated 13F filings for Q4 2023.